Cariprazine Hcl
Brand names: Vraylar
At a glance
- Medicare prescriptions, 2024
- 614,362
- Medicare drug cost
- $892.4M
- Average cost per prescription
- $1,453
- Clinicians who prescribed it
- 20,109
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
1. INDICATIONS AND USAGE VRAYLAR ® is indicated for: • Treatment of schizophrenia in adult and pediatric patients 13 years of age and older • Acute treatment of manic or mixed episodes associated with bipolar I disorder in adult and pediatric patients 10 years of age and older • Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adult patients • Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adult patients
From the FDA-approved prescribing information (label dated December 2025). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. VRAYLAR is not approved for the treatment of patients with dementia-related psychosis. Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for the emergence of suicidal thoughts and behaviors.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Psychiatric Nurse Practitioners 36.7%
- Psychiatry 26.1%
- Nurse Practitioners 14.0%
- Family Medicine 8.7%
- Physician Assistants 6.4%
- Internal Medicine 5.0%
- Child & Adolescent Psychiatry 1.0%
- Neurology 0.4%
- Geriatric Medicine 0.3%
- General Practice 0.3%
- Addiction Medicine 0.2%
- Hospitalist 0.1%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 211% from 2019 to 2024.
Biggest change by state since 2019
- Kentucky +443%
- Georgia +315%
- Florida +264%
- Tennessee +245%
- Louisiana +242%
- California (smallest change) +126%
- Connecticut (smallest change) +158%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Allergan, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 0.5 mg | gray capsule, 14 mm | FL 0 5 |
| 0.75 mg | blue capsule, 14 mm | FL 0 75 |
| 1.5 mg | white capsule, 14 mm | FL 1 5 |
| 3 mg | white capsule, 14 mm | FL 3 |
| 4.5 mg | green capsule, 14 mm | FL 4 5 |
| 6 mg | white capsule, 16 mm | FL 6 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $18.0M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- AbbVie Inc. $18.0M
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Industry-funded trials
- Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder Completed · AbbVie Inc.
- A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. Recruiting · AbbVie Inc.
- Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD Completed · AbbVie Inc.
- Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World Setting Completed · AbbVie Inc.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.